DexCom Inc. (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT)are likely to launch their first over-the-counter (OTC) continuous glucose monitors (CGMs) in the coming months of 2024. Dexcom’s Stelo and Abbott’s Lingo & Libre Rio received FDA clearance in March and June this year, respectively, and now they are up for launch in the coming months of 2024. These devices use the same hardware as past CGMs but are intended for people who do not take insulin. The new devices are likely to allow the companies to reach about 25 million people in the United States with Type 2 diabetes who do not take i…